SHEZF Stock - Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Unlock GoAI Insights for SHEZF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.28B | $5.45B | $7.16B | $6.37B | $5.33B |
| Gross Profit | $1.76B | $944.92M | $2.33B | $2.03B | $2.09B |
| Gross Margin | 33.3% | 17.4% | 32.6% | 31.9% | 39.2% |
| Operating Income | $741.31M | $-860,910,894 | $828.62M | $227.47M | $1.33B |
| Net Income | $646.74M | $-783,258,039.42 | $727.43M | $240.79M | $1.02B |
| Net Margin | 12.2% | -14.4% | 10.2% | 3.8% | 19.2% |
| EPS | $0.44 | $-0.53 | $0.50 | $0.16 | $0.76 |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
Visit WebsiteEarnings History & Surprises
SHEZFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Jun 30, 2025 | $0.00 | $0.03 | +826.8% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $0.01 | $0.01 | +19.5% | ✓ BEAT |
Q4 2024 | Dec 31, 2024 | — | $-0.01 | — | — |
Q4 2024 | Oct 30, 2024 | $0.01 | $0.01 | +14.6% | ✓ BEAT |
Q3 2024 | Aug 28, 2024 | — | $0.05 | — | — |
Q2 2024 | Apr 29, 2024 | — | $0.01 | — | — |
Q1 2024 | Jan 10, 2024 | — | $-0.09 | — | — |
Q3 2023 | Sep 30, 2023 | $0.01 | $0.00 | -80.7% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | — | $0.01 | — | — |
Q1 2023 | Mar 29, 2023 | $0.02 | $0.05 | +155.0% | ✓ BEAT |
Q1 2023 | Jan 1, 2023 | — | $0.01 | — | — |
Q4 2022 | Oct 29, 2022 | $0.03 | $0.01 | -46.5% | ✗ MISS |
Q3 2022 | Aug 29, 2022 | $0.14 | $0.18 | +28.6% | ✓ BEAT |
Q2 2022 | Apr 29, 2022 | $0.12 | $0.03 | -79.0% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-0.02 | — | — |
Q4 2021 | Oct 27, 2021 | $0.17 | $0.01 | -92.3% | ✗ MISS |
Q3 2021 | Aug 26, 2021 | $0.18 | $0.02 | -88.6% | ✗ MISS |
Q2 2021 | Apr 28, 2021 | — | $0.01 | — | — |
Q4 2020 | Dec 31, 2020 | — | $0.03 | — | — |
Q4 2020 | Oct 29, 2020 | $0.14 | $0.09 | -35.7% | ✗ MISS |
Latest News
Frequently Asked Questions about SHEZF
What is SHEZF's current stock price?
What is the analyst price target for SHEZF?
What sector is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in?
What is SHEZF's market cap?
Does SHEZF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SHEZF for comparison